Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

RecruitingOBSERVATIONAL
Enrollment

908

Participants

Timeline

Start Date

October 27, 2023

Primary Completion Date

July 6, 2032

Study Completion Date

July 6, 2032

Conditions
Multiple Sclerosis
Interventions
DRUG

Diroximel Fumarate

Administered as specified in the treatment arm.

DRUG

Avonex

Administered as specified in the treatment arm.

BIOLOGICAL

Tysabri

Administered as specified in the treatment arm.

DRUG

Dimethyl Fumarate

Administered as specified in the treatment arm.

Trial Locations (7)

3010

RECRUITING

Inselspital, Bern

3084

RECRUITING

Austin Hospital, Heidelberg

27703

RECRUITING

IQVIA US Office, Durham

28034

RECRUITING

Hospital Universitario Ramon y Cajal, Madrid

44791

RECRUITING

Katholisches Klinikum Bochum, Bochum

80045

RECRUITING

University of Colorado Anschutz Medical Campus, Aurora

DO4 T6F4

RECRUITING

St Vincent's University Hospital, Dublin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY